The following is a summary of the Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript:

Financial Performance:

• Innate Pharma has a firm cash status with about EUR115 million in cash as of the end of March 2024, expected to back the company's operations till the end of 2025.

Business Progress:

• The company's approach is to add value by advancing early R&D efforts through later-stage partnerships, making notable progress with lacutamab and IPH65, amongst others.

• Innate Pharma underlined their contributions to ongoing trials and future strategy for IPH45 and lacutamab, both from the ANKET platform.

• Their investment in Antibody Drug Conjugates (ADCs) is showcased with the progression of proprietary asset IPH45.

• There are anticipated milestones, including the data presentation of lacutamab, IPH65, and monalizumab in trials at the ASCO conference.

• The company is also expected to file an IND for IPH45 this year.

• Lacutamab might seek accelerated approval under a fast-to-market strategy for Sezary syndrome, and aims for MF patients as well.

• For PTCL treatment, lacutamab seeks to establish a balance between treatment effectiveness and tolerability, especially for patients who cannot endure harsher therapies.

More details: Innate Pharma IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.